A1C Almanac

Main Page

Why Your Midlife Body Ignores the Rules: The Muscle Loss and Blood Sugar Connection Behind “Stubborn” Weight Gain

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:

Why Midlife Weight Gain Feels “Sudden”

Midlife weight gain is often experienced as a “sudden” loss of metabolic control: patients in their 40s or 50s report that long-standing eating and exercise habits no longer maintain a stable weight, with progressive tightening of clothes and a characteristic shift of adiposity toward the abdomen. This subjective sense of a rapid change is widely echoed in clinical practice and population surveys, yet longitudinal cohort studies indicate that it sits atop a much longer and quitter trajectory beginning in early mid-adulthood. Large prospective analyses show that incremental increases in body weight and central adiposity across midlife are strongly patterned by earlier changes in body composition and lifestyle and midlife trajectories of weight and waist circumference predicting downstream risks of diabetes, cardiovascular disease, and mortality.

Mechanistic work helps explain why this inflection point feels abrupt despite its long prodrome. From the third decade onward, skeletal muscle mass and strength decline by an estimated 3-8% per decade in the absence of focused resistance training, reducing resting energy expenditure and diminishing the primary peripheral sink for postprandial glucose disposal. In parallel, subtle shifts in sex steroids, growth hormone/ IGF-1, and thyroid axis activity occur within “normal” reference ranges, collectively favoring fat accretion and reducing insulin sensitivity without triggering overt endocrine diagnoses. Over time, these changes contribute to mounting insulin resistance, higher postprandial glucose excursions, and preferential visceral fat storage, even when weight remains apparently “stable” on annual check-ups. The result I that by the time patients notice visible abdominal fat gain and “stubborn” weight in their 40s-50s, the underlying musculoskeletal and hormonal shifts have often been progressing silently for a decade or more.

Viewed through a preventive medicine and digital health lens, midlife weight gain is therefore better conceptualized as the late, visible manifestation of a long biological trajectory rather than an isolated lapse in discipline. This reconceptualization has practical implications: it shifts clinical focus from reactive prescription of diets or pharmacotherapy after significant weight gain to earlier surveillance of muscle mass, visceral adiposity, and glycemic dynamics beginning in the 30s. integrating body composition assessment, continuous or intermittent glucose monitoring, sleep metrics, and stress indicators into routine midlife care enables identification of inflection points such as declining lean mass or widening postprandial glucose swings years before overt obesity or diabetes emerge. For health-tech platforms, embedding these signals into algorithms and user interfaces can help reframe midlife weight gain for patients as a modifiable biological process, guiding them toward interventions that prioritize muscle preservation, glycemic stability, and recovery rather than simplistic calorie counting once problems are already entrenched.

The Silent Shift: Hormones, Muscle, and Fat in Your 30s-40s

Endocrine aging across the third and fourth decades is marked less by dramatic laboratory abnormalities than by a slow erosion of hormonal signals that support lean mass, insulin sensitivity, and energy expenditure. Growth hormone and IGF‑1 secretion decline progressively from young adulthood onward, with estimates suggesting a roughly 10–15% fall in GH output per decade and substantial reductions in circulating IGF‑1, changes that correlate with loss of skeletal muscle, increased visceral adiposity, and reduced physical performance. In parallel, sex steroid levels begin a gradual descent: in men, longitudinal studies document annual declines in total and bioavailable testosterone from the third decade, while in women, ovarian hormonal output becomes increasingly erratic as perimenopause approaches. Thyroid function may remain within reference ranges but often shows subtle shifts in TSH and peripheral thyroid hormone metabolism with age, contributing to modest reductions in basal metabolic rate that are rarely recognized in routine clinical care [1,2,3,4,5].

Figure 1. Aging results in decline in anabolic hormone production and, as is true for a large sum of the older population, a habitual decline in physical activity

These hormonal drifts exert convergent effects on body composition. Reduced GH/IGF‑1 signalling lowers protein synthesis and blunts lipolysis, particularly in visceral depots, thereby promoting sarcopenia and central fat accumulation. Declining sex steroids further impair muscle protein anabolism and favour fat storage; testosterone and estrogen both modulate muscle maintenance and adipose distribution, so their age‑related decline is linked to higher fat mass and lower lean mass even in individuals whose diet and physical activity appear unchanged. The net result in many adults in their 30s–40s is a quiet shift toward sarcopenic obesity, a phenotype characterized by shrinking muscle and expanding abdominal fat well before BMI crosses an “overweight” threshold [1,2,5,6,7].

Superimposed on this background are sex‑specific patterns. In women, the perimenopausal transition is accompanied by fluctuating and then declining estradiol levels, which impair insulin sensitivity and promote a redistribution of fat from gluteofemoral to abdominal depots, increasing visceral adiposity even when total body weight changes minimally. Estrogen withdrawal is also associated with sleep fragmentation, vasomotor symptoms, and mood disturbance, all of which feed back into appetite regulation, cortisol dynamics, and physical activity, creating a “perfect storm” for central weight gain. In men, gradual reductions in circulating testosterone are linked to decreased muscle mass and strength, increased fat mass, and higher prevalence of metabolic syndrome and type 2 diabetes, with sarcopenia and visceral obesity emerging as key clinical manifestations [2,6,8,9].

Modern environmental and behavioural exposures magnify these endocrine trends. Chronic psychosocial stress, irregular sleep, and high intake of ultra‑processed, energy‑dense foods all interact with an aging hypothalamic–pituitary–adrenal axis and declining anabolic hormones to further tilt energy balance toward storage rather than utilization. Sleep restriction and circadian disruption increase ghrelin, reduce leptin, and elevate evening cortisol, potentiating appetite, impairing glucose tolerance, and favouring abdominal fat deposition effects that are amplified when baseline estrogen or testosterone levels are already falling. Taken together, these hormonal and lifestyle factors help explain why body composition often deteriorates in the 30s and 40s, decades before traditional chronological definitions of “old age,” and why midlife weight gain reflects a long‑running endocrine and musculoskeletal shift rather than a sudden change in behaviour [1,5,6,8,9].

Muscle as a Metabolic Organ: The First Domino

Skeletal muscle is now recognized as a central metabolic organ rather than merely a locomotor tissue, with a disproportionate role in maintaining glucose homeostasis and energy balance. Under hyperinsulinemic-euglycemic clamp conditions, approximately 70-80% of insulin-stimulated glucose uptake occurs in skeletal muscle, making it the principal sink for clearing postprandial glucose from the circulation in non-obese individuals. This dominant contributions explains why skeletal muscle insulin resistance is considered the primary defect in the pathogenesis of type 2 diabetes; defect in muscle glucose uptake alone can largely account for disturbances in whole-body glucose disposal and glycemic control. Beyond its role in insulin-dependent uptake, muscle also mediates contraction-induced, insulin-independent glucose transport during and after physical activity, further reinforcing its status as a dynamic regulator of systemic glucose flux [10,11,12,13,14].

From early midlife onward, age-related changes in muscle mass and quality progressively undermine this regulatory capacity. Longitudinal and cross‑sectional data indicate that adults typically lose about 3–8% of muscle mass per decade after the age of 30, with losses in strength often outpacing losses in mass. Histological and imaging studies show a reduction in muscle fiber number and cross‑sectional area with aging, accompanied by denervation, motor unit remodelling, and “anabolic resistance” to dietary protein and exercise. Even before overt weakness or disability emerges, this decline in contractile tissue reduces resting energy expenditure and narrows the margin between daily energy intake and energy needs, making positive energy balance and fat gain more likely at a given calorie intake [15,16,17,18].

Crucially, early sarcopenia often develops in individuals whose BMI remains in the “normal” or only mildly elevated range, masking clinically important losses of lean mass behind stable or slowly rising body weight. Meta‑analytic data and clinical cohorts demonstrate that low muscle mass and strength are associated with higher fasting glucose, HOMA‑IR, triglycerides, and blood pressure, as well as adverse lipid profiles, even after adjustment for BMI, supporting the concept that sarcopenia independently worsens metabolic risk. In this context, the gradual erosion of muscle in the 30s and 40s functions as a “first domino”: as the primary glucose-handling and calorie-burning engine shrinks, the body’s capacity to buffer dietary carbohydrate and maintain energy balance contracts, while daily caloric exposure and lifestyle stresses (sedentariness, sleep loss, ultra-processed foods) often remain constant or intensify [10,15,19,20].

The mismatch between diminishing muscle and unchanged or increasing metabolic load leads to a characteristic cascade. With less muscle available, a given oral glucose load produces higher and more prolonged glycemic excursions, demanding greater insulin secretion and promoting insulin resistance over time. Simultaneously, lower resting and activity‑related energy expenditure makes it easier for small caloric surpluses to be stored as fat, particularly in visceral depots that further exacerbate insulin resistance and systemic inflammation. By the time midlife patients present with central adiposity, impaired fasting glucose, or frank diabetes, years of unrecognized muscle loss have often already set this trajectory in motion, underscoring the need to treat skeletal muscle as an early, modifiable target in metabolic prevention rather than a late marker of frailty [10,11,18,19,20].

Less Muscle, Bigger Blood Sugar Swings

Skeletal muscle is the principal peripheral organ responsible for clearing glucose from the circulation after a mixed or carbohydrate‑rich meal, accounting for roughly 70–80% of insulin‑stimulated glucose uptake under physiological conditions. Hyperinsulinemic–euglycemic clamp and tracer studies consistently show that, in healthy individuals, the vast majority of glucose disposal in the postprandial state occurs in skeletal muscle rather than adipose tissue or liver, which means that the total “volume” of functioning muscle fibers effectively sets the ceiling for how much glucose can be cleared within a given time window. When muscle mass is reduced, whether through age-related sarcopenia, inactivity, or illness, this ceiling drops: identical meals that previously produced modest excursions now yield higher glycemic peaks and a slower return to baseline, increasing overall glycemic variability despite unchanged dietary intake [10,21,22,23,24].

The impact of muscle loss on glucose dynamics is not limited to insulin‑dependent pathways. During and after physical activity, skeletal muscle can take up glucose through contraction‑mediated, insulin‑independent mechanisms involving calcium signalling, AMP‑activated protein kinase, and GLUT4 translocation, which augment or even bypass classical insulin signalling. Individuals with less muscle mass typically have lower absolute amounts of contractile tissue engaged during daily tasks, and sarcopenia is frequently accompanied by reductions in non‑exercise activity and spontaneous movement, further diminishing contraction‑mediated glucose disposal over the course of the day. The combined loss of insulin‑stimulated and contraction‑induced uptake means that a smaller fraction of ingested glucose is rapidly sequestered into muscle glycogen and oxidation, leaving more in the circulation to be handled by other tissues or converted to fat [10,13,19,21,24,25].

Clinical and epidemiologic data increasingly support the concept that “muscle‑poor” phenotypes are intrinsically more prone to blood sugar swings and poorer long‑term glycemic control. Cross‑sectional and cohort studies in older adults with type 2 diabetes report that lower lean mass and muscle mass percentiles are associated with higher HbA1c values, greater oxidative stress, and worse indices of metabolic control, even after adjusting for BMI. Observational work further links low lean mass to impaired estimated glucose disposal rate and to the coexistence of sarcopenia with obesity and insulin resistance, suggesting a bidirectional relationship in which reduced muscle promotes hyperglycemia and hyperglycemia, in turn, exacerbates muscle loss. Emerging CGM‑based studies and meta‑analyses indicate that poor glycemic control and larger day‑to‑day glycemic fluctuations are associated with higher risk of sarcopenia, while higher HbA1c and greater glycemic variability correlate with lower muscle mass and strength in adults with diabetes. Together, these findings support a mechanistic and clinical view in which declining muscle mass narrows the body’s capacity to buffer glucose, amplifying postprandial peaks and glycemic variability long before fasting glucose becomes abnormal, and placing individuals with low lean mass on a steeper trajectory toward overt dysglycemia and cardiometabolic disease [10,11,19,20,21,22,25,27,28].

From Glycemic Swings to Fat Gain and “Stubborn” Weight

Frequent and exaggerated postprandial glucose excursions after meals trigger correspondingly large and prolonged insulin secretory responses to maintain glycemic control. Over time, chronic hyperinsulinemia exerts direct anabolic effects on adipose tissue, stimulating adipocyte lipogenesis, promoting free fatty acid uptake via enhanced FATP1 and CD36 translocation to adipocyte membranes, and suppressing lipolysis by reducing cAMP signalling and hormone-sensitive lipase activity. In physiological terms, insulin levels on the high side of normal are sufficient to inhibit lipolysis and activate lipogenesis in adipocytes, while much higher concentrations are required to affect glucose transport in muscle or hepatic glucose production. This differential sensitivity means that moderate hyperinsulinemia preferentially drives fat storage even when glucose homeostasis appears intact, a phenomenon increasingly recognized as a primary promoter of body fat gain in individuals with insulin hypersecretion [29,30,31,32,33,34].

In midlife, the combination of declining muscle mass, rising glycemic variability, and hormonal changes creates an environment in which surplus energy is channelled disproportionately into visceral and hepatic fat depts rather than subcutaneous adipose tissue. When subcutaneous adipose tissue’s capacity to safely store excess lipid is exceeded or compromised, a phenomenon resembling subtle partial lipodystrophy fat is redirected as ectopic deposition into liver, pancreas, skeletal muscle, and visceral compartments. These ectopic lipid depts drive insulin resistance locally through lipotoxicity, mitochondrial dysfunction, oxidative stress, and endoplasmic reticulum stress, further impairing insulin signalling and perpetuating a cycle of hyperinsulinemia and fat gain [35,36,37,38].

Figure 2. The Effects of decreasing muscle mass [38]

Visceral adiposity, in particular, amplifies whole-body insulin resistance through multiple mechanisms. Visceral fat is metabolically distinct from subcutaneous fat, exhibiting higher lipolytic activity, greater macrophage infiltration, and increased secretion of pro-inflammatory cytokines including TNF-α, IL-6, and resistin, alongside reduced adiponectin output. These inflammatory mediators activate stress-responsive kinases such as JNK and IKKβ in skeletal muscle, liver, and adipose tissue, impairing insulin receptor signalling and perpetuating systemic insulin resistance. Ectopic fat accumulation in skeletal muscle (myosteatosis) further reduces muscle quality, promotes additional muscle loss through lipotoxicity and oxidative damage, and lowers contraction-mediated glucose uptake, tightening the vicious cycle: more muscle loss leads to higher postprandial glucose and insulin swings, which drive more visceral and ectopic fat deposition, which further exacerbates insulin resistance and accelerates sarcopenia [36,38,39,40,41,42,43,44,45].

Clinically, this self-reinforcing loop manifests as the classic midlife pattern of “stubborn” central weight gain despite subjectively unchanged eating habits, often accompanied by symptoms of reactive hypoglycemia such as shakiness, irritability, fatigue, hunger, and energy crashes occurring 2–5 hours after meals. Reactive hypoglycemia arises when an initial glucose spike triggers delayed but excessive second-phase insulin secretion due to loss of first-phase insulin response, characteristic of early insulin resistance and impaired glucose tolerance. The resulting late hyperinsulinemia drives blood glucose below baseline, producing symptomatic hypoglycemia and prompting hunger and further carbohydrate intake, perpetuating the cycle. Epidemiologic and prospective data indicate that individuals with late reactive hypoglycemia, particularly those with obesity and family history of diabetes, are at significantly higher risk of progressing to prediabetes and type 2 diabetes. Together, these metabolic and symptomatic changes explain why midlife patients often report feeling “stuck” despite conventional dietary efforts: the underlying biology, sarcopenia, glycemic instability, hyperinsulinemia, and ectopic fat accumulation drives weight gain and energy volatility through mechanisms that simple calorie restriction or cardio exercise cannot address [35,38,43,46,47,48,49,50,51].

Why “Eat Less, Move More” Fails Midlife Biology

The standard approach to midlife weight gain advising patients simply to “eat less and move more” fails to account for the underlying biology that distinguishes midlife metabolism from that of younger adults. Conventional calorie restriction (CR) induces a reduction in total energy expenditure that is larger than expected based solely on loss of metabolic mass, a phenomenon termed metabolic adaptation. This disproportionate drop in resting energy expenditure, estimated at approximately 5–10% beyond what is attributable to changes in body mass alone, reflects reductions in organ mass (particularly skeletal muscle and kidney), declines in circulating insulin, leptin, and thyroid hormones, and increased mitochondrial efficiency. While these adaptations may confer longevity benefits in controlled research settings, they also limit the efficacy of calorie restriction for long‑term weight management, particularly when muscle preservation is not prioritized [52,53,54,55].

More critically, calorie restriction without concurrent resistance training and adequate protein intake accelerates the very losses of fat‑free mass and muscle that underlie midlife metabolic dysfunction. CALERIE trial data and subsequent analyses show that CR consistently induces significant reductions in lean body mass alongside fat loss, with older adults experiencing proportionally greater declines in muscle strength and aerobic capacity than younger individuals. In postmenopausal women undergoing energy restriction, for example, fat‑free mass declined unless resistance training was incorporated into the intervention; those who performed resistance training preserved muscle while achieving similar fat loss to sedentary dieters. The preservation of muscle during weight loss is especially important in midlife because muscle mass is already declining at 3–8% per decade; further losses from poorly designed diets exacerbate sarcopenia, lower resting energy expenditure, impair glucose handling, and paradoxically increase body fat percentage even at stable or reduced body weight [18,52,56,57,58].

Figure 3. Changes in Weight and Body Composition in Midlife Women and Clinical Consequences [58]

Compounding these issues, many midlife patients respond to weight gain by increasing cardiovascular exercise, particularly steady‑state aerobic work, without balancing it with strength training or addressing recovery. Prolonged or high‑intensity aerobic exercise elevates cortisol significantly more than resistance training of comparable duration, and this cortisol response is further amplified by inadequate caloric intake, insufficient sleep, or advanced age. Chronically elevated cortisol promotes muscle protein catabolism, inhibits muscle protein synthesis, and preferentially channels amino acids from muscle breakdown into gluconeogenesis for energy rather than anabolic processes. The net effect is progressive loss of lean muscle tissue, increased intramuscular adipose tissue, and rising central adiposity despite adherence to a regimen of calorie restriction and cardio‑based exercise [59,60,61,62,63].

This paradox becoming lighter in muscle but heavier in fat underlies the clinical frustration many midlife patients express when they report that “nothing works anymore.” Their subjective experience reflects a biological reality: without deliberate preservation of muscle through resistance training and protein optimization (typically ³1.0-1.2 g/kg/day, and higher in older adults with anabolic resistance), conventional weight‑loss strategies erode the very tissue responsible for glucose buffering, energy expenditure, and metabolic resilience. As muscle declines and cortisol‑driven catabolism persists, blood sugar becomes more volatile, insulin resistance worsens, and the capacity for sustained fat loss diminishes, reinforcing a cycle of dietary restriction, muscle loss, metabolic slowdown, and weight regain often with worsened body composition. In this context, advice to “eat less, move more” not only fails to address the root causes of midlife weight gain but may actively accelerate the muscle loss, hormonal dysregulation, and metabolic decline that drive it [34,52,57,59,61,62,63].

Prevention and Intervention: Protecting Muscle to Flatten the Curve

A biology‑aligned midlife metabolic strategy shifts focus away from simple calorie restriction or generic advice to “move more,” instead prioritizing the preservation and rebuilding of skeletal muscle as the central lever for metabolic health, glucose control, and sustainable fat loss. Progressive resistance training (RT) has emerged as the most effective non‑pharmacological intervention for this purpose, with recent meta‑analyses showing that RT in middle‑aged and older adults (aged 50+) consistently improves insulin sensitivity (measured as HOMA‑IR, fasting insulin, and fasting glucose), glycemic control (HbA1c), muscle mass, and strength, while also reducing systemic inflammation (CRP). These improvements in insulin resistance and glucose disposal are mechanistically linked to increases in muscle mass, fiber hypertrophy, and upregulation of GLUT4 and insulin signalling pathways in skeletal muscle, as well as enhanced contraction‑mediated glucose uptake. Importantly, RT‑induced gains in lean mass not only increase the absolute capacity for postprandial glucose clearance but also raise resting energy expenditure, counteracting the age‑related decline in basal metabolic rate that underlies midlife fat gain [64,65].

Equally critical to muscle preservation is the optimization of dietary protein intake, both in total quantity and in distribution pattern across meals. Older adults exhibit “anabolic resistance,” requiring higher per‑meal doses of protein and specifically higher leucine content to maximally stimulate muscle protein synthesis (MPS) compared to younger individuals. Current evidence suggests that consuming at least 0.4 g/kg body weight of high‑quality protein per meal, distributed evenly across breakfast, lunch, and dinner, is superior to a skewed pattern (e.g., low protein at breakfast and high at dinner) for promoting net daily MPS and preserving lean mass during aging. This “per‑meal threshold” model is supported by controlled trials demonstrating that an even distribution pattern (~30 g protein per meal, providing ≥2.5–2.8 g leucine) increases 24‑hour MPS by approximately 25% compared to uneven patterns at the same total daily protein intake. Mechanistically, the limited duration of post‑meal MPS (~2–3 hours) means that a single large protein meal cannot fully compensate for low intake at other meals; instead, repeated stimulation across the day optimizes cumulative anabolism and attenuates muscle loss [66,67,68,69,70].

Layered onto these muscle‑centric interventions are dietary patterns and activity timing strategies that directly blunt postprandial glucose excursions and reduce the hyperinsulinemic burden that drives fat storage. Diets emphasizing minimally processed, fiber‑rich whole foods, balanced macronutrients, and adequate protein have been shown to reduce glycemic variability and insulin demand. When combined with “walking the curve”, a strategy of light-to moderate-intensity walking immediately after meals, the effectiveness of dietary interventions is further amplified. Multiple controlled trials in healthy adults and individuals with type 2 diabetes show that 10–30 minutes of postprandial walking started immediately after a meal significantly lowers the glucose peak, reduces 2‑hour postprandial glucose area under the curve (AUC), and decreases 24‑hour glycemic variability and standard deviation. The effect is robust across different meal compositions (high vs. lower carbohydrate, mixed meals vs. glucose drinks), and notably, even brief 10–15 minute walks are effective when started immediately, suggesting that the timing of activity relative to nutrient absorption is as important as duration [71,72,73,74,75].

The Role of AI and Digital Health in The Midlife Window

Artificial intelligence and digital health tools are uniquely positioned to detect the earliest signatures of midlife metabolic drift, long before BMI or standard labs cross abnormal thresholds. AI‑integrated continuous glucose monitoring (CGM) systems, for example, can transform raw glucose traces into high‑resolution metrics of glycemic variability, time‑in‑range, and meal‑specific responses, enabling precise identification of prediabetes and subtle dysglycemia that would be missed by periodic fasting glucose or HbA1c alone. Deep learning models trained on CGM data can characterize intra‑day and inter‑day patterns, predict future glucose excursions, and flag “high‑risk days” or food–glucose combinations that disproportionately drive spikes, supporting earlier and more personalized intervention [76,77,78,79].

Parallel advances in automated body composition analysis allow AI systems to quantify muscle mass, muscle quality, and visceral fat opportunistically from routine imaging or dedicated scans. Prospective studies have demonstrated that fully automated deep learning pipelines can segment muscle and fat compartments on CT with high Dice similarity coefficients (>0.9), derive skeletal muscle index and fatty muscle fraction, and classify sarcopenia with high accuracy and area under the curve (AUC ≈ 0.87–0.97). These pipelines can be integrated into routine health check‑ups to provide “muscle age,” visceral fat area, and sarcopenia risk without additional radiation or workflow burden, effectively turning existing imaging into a continuous surveillance tool for muscle decline and myosteatosis in midlife adults. Machine‑learning models built on anthropometrics, lab values, and functional tests can further enhance screening in settings without imaging, offering scalable risk scores for sarcopenia and sarcopenic obesity [39,43,80,81,82,83].

When multimodal data streams are combined, CGM metrics, body composition, wearable-derived activity and sleep data, diet logs, and electronic health record, AI can defect atterns that signal a high‑risk midlife transition even when weight appears stable. Bibliometric and methodological reviews emphasize that AI in metabolic disease is rapidly evolving from single‑modality prediction toward integrated platforms that synthesize smart‑device data for early detection and individualized intervention. For example, pattern‑recognition models can identify when a patient’s weight is unchanged but lean mass and step volume are drifting downward, while visceral fat metrics and glucose excursions to habitual meals are creeping upward, a constellation that indicates “becoming softer” and more insulin resistant rather than simply “staying the same.” Such systems can generate proactive alerts to clinicians or users, flagging the need to evaluate muscle mass, strength, and glycemic control before overt diabetes or frailty develops [76,80,81,84,75].

Beyond detection, AI‑enabled platforms increasingly serve as engines for personalized, just‑in‑time lifestyle and treatment recommendations. Integrated digital health programs for type 2 diabetes that combine CGM, AI‑based dietary analysis, and app‑delivered coaching have shown improvements in glycemic control, including reductions in HbA1c and weight, by tailoring food choices, meal timing, and activity plans to each individual’s glucose responses and routines. Systematic reviews of AI in health promotion and chronic disease management report that AI‑powered mobile apps and chatbots can enhance engagement, increase physical activity, improve diet quality, and modestly improve cardiometabolic markers across conditions such as obesity, hypertension, and diabetes. In a midlife context, similar architectures could be adapted to prioritize resistance‑training prescriptions, protein distribution targets, post‑meal “glucose walks,” and sleep–stress interventions, dynamically adjusting recommendations based on observed changes in muscle metrics, CGM profiles, and wearable‑derived data [76,77,79,80,85,86,87].

Weight As a Late Signal of Muscle and Glucose Biology

Midlife weight gain is most accurately interpreted as a late, visible manifestation of earlier, interacting biological shifts rather than as a simple failure of discipline. Years of gradually shrinking skeletal muscle mass, subtle but cumulative changes in anabolic and sex hormones, and progressively widening postprandial glucose excursions together create an internal milieu that favors fat storage, particularly in visceral and hepatic depots, long before the bathroom scale shows a dramatic change. Framing weight in this way as a downstream readout of muscle quantity and quality, endocrine tone, and glycemic stability moves the discussion from individual willpower toward a systems-level understanding of metabolic aging that better matches both clinical data and patient experience.

Within this framework, muscle and glucose handling emerge as primary levers for midlife and later‑life health rather than secondary considerations. Treating skeletal muscle as a “vital sign” and glycemic variability as a dynamic biomarker of metabolic youth encourages earlier, more targeted intervention in the 30s and 40s, when sarcopenia, visceral fat accumulation, and postprandial dysglycemia are still modifiable and often subclinical. For clinicians and AI‑enabled health‑tech platforms, this implies a shift in midlife counselling from the generic prescription to “eat less, move more” toward a more precise mandate: “build and protect muscle, and flatten your blood sugar curve.” In this model, weight stability and waist control become emergent outcomes of preserved muscle mass, improved insulin sensitivity, and dampened glycemic swings, rather than the primary therapeutic targets themselves a reframing that better aligns preventive practice with the underlying biology of midlife weight gain

Reference

  1. Pataky MW, Young WF, Nair KS. Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications. Mayo Clinic Proceedings [Internet]. 2021 Mar 1;96(3):788–814. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0025619620309228
  2. Basualto-Alarcón C, Varela D, Duran J, Maass R, Estrada M. Sarcopenia and Androgens: A Link between Pathology and Treatment. Frontiers in Endocrinology [Internet]. 2014 Dec 18;5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270249/
  3. Sellami M, Dhahbi W, Hayes LD, Padulo J, Rhibi F, Djemail H, et al. Combined sprint and resistance training abrogates age differences in somatotropic hormones. Lucía A, editor. PLOS ONE. 2017 Aug 11;12(8):e0183184.
  4. Garcia JM, Merriam GR, Kargi AY. Growth Hormone in Aging [Internet]. Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al., editors. PubMed. South Dartmouth (MA): MDText.com, Inc.; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279163/
  5. Cappola AR, Auchus RJ, Ghada El-Hajj Fuleihan, Handelsman DJ, Kalyani RR, McClung MR, et al. Hormones and Aging: An Endocrine Society Scientific Statement. The Journal of Clinical Endocrinology and Metabolism. 2023 Jun 16;108(8):1835–74.
  6. Yu D, Zhou B. Sarcopenic Obesity and Hormones: A Narrative Review. Journal of Biosciences and Medicines [Internet]. 2025 [cited 2026 Jan 26];13(12):18–35. Available from: https://www.scirp.org/journal/paperinformation?paperid=147735
  7. Witzel J. Hormonal Changes in Aging: From Growth Hormone to Sex Steroids. [cited 2026 Jan 26]; Available from: https://www.walshmedicalmedia.com/open-access/hormonal-changes-in-aging-from-growth-hormone-to-sex-steroids.pdf
  8. Integrative Medicine Hong Kong | IMI Holistic Clinic [Internet]. Imi.com.hk. 2026 [cited 2026 Jan 26]. Available from: https://www.imi.com.hk/en/understanding-perimenopause-and-its-impact-on-metabolic-health
  9. The Connection Between Menopause & Belly Fat [Internet]. www.uhhospitals.org. Available from: https://www.uhhospitals.org/blog/articles/2023/08/the-connection-between-menopause-and-belly-fat
  10. Merz KE, Thurmond DC. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. Comprehensive Physiology [Internet]. 2020 Jul 8;10(3):785–809. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8074531/
  11. DeFronzo RA, Tripathy D. Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes. Diabetes Care. 2009 Oct 29;32(suppl_2):S157–63.
  12. P Nuutila, M Mäki, Laine H, Knuuti MJ, U Ruotsalainen, M Luotolahti, et al. Insulin action on heart and skeletal muscle glucose uptake in essential hypertension. Journal of Clinical Investigation. 1995 Aug 1;96(2):1003–9.
  13. Cartee GD. Mechanisms for greater insulin-stimulated glucose uptake in normal and insulin-resistant skeletal muscle after acute exercise. American Journal of Physiology-Endocrinology and Metabolism. 2015 Dec 15;309(12):E949–59.
  14. Verbrugge SAJ, Alhusen JA, Kempin S, Pillon NJ, Rozman J, Wackerhage H, et al. Genes controlling skeletal muscle glucose uptake and their regulation by endurance and resistance exercise. Journal of Cellular Biochemistry. 2021 Nov 23;123(2):202–14.
  15. Muscle Strength Decreases with Age. How Can You Slow It Down? [Internet]. http://www.healthylongevity.clinic. Available from: https://www.healthylongevity.clinic/blog/muscle-strength
  16. Mary Anne Dunkin. Sarcopenia With Aging [Internet]. WebMD. 2022. Available from: https://www.webmd.com/healthy-aging/sarcopenia-with-aging
  17. Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Current opinion in clinical nutrition and metabolic care [Internet]. 2004;7(4):405–10. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2804956/
  18. Wilkinson DJ, Piasecki M, Atherton PJ. The age-related loss of skeletal muscle mass and function: Measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans. Ageing Research Reviews [Internet]. 2018 Nov;47:123–32. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202460/
  19. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia Exacerbates Obesity-Associated Insulin Resistance and Dysglycemia: Findings from the National Health and Nutrition Examination Survey III. Earnest CP, editor. PLoS ONE. 2010 May 26;5(5):e10805.
  20. He Q, Wang X, Yang C, Zhuang X, Yue Y, Jing H, et al. Metabolic and Nutritional Characteristics in Middle-Aged and Elderly Sarcopenia Patients with Type 2 Diabetes. Tatti P, editor. Journal of Diabetes Research. 2020 Nov 4;2020:1–8.
  21. Hulett NA, Scalzo RL, Reusch JEB. Glucose Uptake by Skeletal Muscle within the Contexts of Type 2 Diabetes and Exercise: An Integrated Approach. Nutrients. 2022 Feb 3;14(3):647.
  22. Alabadi B, Civera M, De la Rosa A, Martinez-Hervas S, Gomez-Cabrera MC, Real JT. Low Muscle Mass Is Associated with Poorer Glycemic Control and Higher Oxidative Stress in Older Patients with Type 2 Diabetes. Nutrients [Internet]. 2023 Jul 17;15(14):3167. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383462/
  23. Kondash ME, Ananthakumar A, Khodabukus A, Bursac N, Truskey GA. Glucose Uptake and Insulin Response in Tissue-engineered Human Skeletal Muscle. Tissue Engineering and Regenerative Medicine. 2020 Mar 21;
  24. Honka MJ, Latva-Rasku A, Bucci M, Virtanen KA, Hannukainen JC, Kalliokoski KK, et al. Insulin-stimulated glucose uptake in skeletal muscle, adipose tissue and liver: a positron emission tomography study. European Journal of Endocrinology [Internet]. 2018 Mar 7;178(5):523–31. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920018/
  25. Du Y, Oh C, No J. Associations between Sarcopenia and Metabolic Risk Factors: A Systematic Review and Meta-Analysis. Journal of Obesity & Metabolic Syndrome. 2018 Sep 30;27(3):175–85.
  26. Chen Y, Gao L, Song X, Wu M, Li R, Su K, et al. The relationship between estimated glucose disposal rate and sarcopenia among middle-aged and older adults. Scientific Reports [Internet]. 2025 Dec 3 [cited 2026 Jan 26];16(1). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12796166/
  27. Lin S, Andrikopoulos S, Shi YC, Sibbritt D, Peng W. Exploring the relationship between glycemic variability and muscle dysfunction in adults with diabetes: A systematic review. Reviews in Endocrine and Metabolic Disorders. 2025 Jan 29;
  28. Qiao YS, Chai YH, Gong HJ, Zhuldyz Z, Stehouwer CDA, Zhou JB, et al. The Association Between Diabetes Mellitus and Risk of Sarcopenia: Accumulated Evidences From Observational Studies. Frontiers in Endocrinology. 2021 Dec 23;12.
  29. Ali AH, Mundi M, Koutsari C, Bernlohr DA, Jensen MD. Adipose Tissue Free Fatty Acid Storage In Vivo: Effects of Insulin Versus Niacin as a Control for Suppression of Lipolysis. Diabetes [Internet]. 2015 Apr 16 [cited 2026 Jan 7];64(8):2828–35. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4512218/?utm_source=chatgpt.com
  30. Kolb H, Stumvoll M, Kramer W, Kempf K, Martin S. Insulin translates unfavourable lifestyle into obesity. BMC Medicine. 2018 Dec;16(1).
  31. Richard AJ, White U, Elks CM, Stephens JM. Adipose Tissue: Physiology to Metabolic Dysfunction [Internet]. PubMed. South Dartmouth (MA): MDText.com, Inc.; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555602/
  32. Domenico Tricò, Chiriacò M, Nouws J, Vash-Margita A, Romy Kursawe, Tarabra E, et al. Alterations in adipose tissue distribution, cell morphology and function mark primary insulin hypersecretion in youths with obesity. Diabetes. 2023 Oct 23;73(6):941–52.
  33. O’Donovan SD, Lenz M, Vink RG, Nadia, Theo, Edwin, et al. A computational model of postprandial adipose tissue lipid metabolism derived using human arteriovenous stable isotope tracer data. PLoS Computational Biology. 2019 Oct 3;15(10):e1007400–0.
  34. Mittendorfer B, Johnson JD, Solinas G, Jansson PA. Insulin Hypersecretion as Promoter of Body Fat Gain and Hyperglycemia. Diabetes [Internet]. 2024 May 20;73(6):837–43. Available from: https://diabetesjournals.org/diabetes/article/73/6/837/154590/Insulin-Hypersecretion-as-Promoter-of-Body-Fat
  35. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine reviews [Internet]. 2002;23(2):201–29. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11943743/
  36. Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. The Lancet Diabetes & Endocrinology [Internet]. 2019 Sep;7(9):715–25. Available from: https://www.sciencedirect.com/science/article/pii/S2213858719300841
  37. The Causal Role of Ectopic Fat Deposition in the Pathogenesis of Metabolic Syndrome. International Journal of Molecular Sciences [Internet]. 2024 Dec 10;25(24):13238–8. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11675790/
  38. Li C, Yu K, Shyh‐Chang N, Jiang Z, Liu T, Ma S, et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. Journal of Cachexia, Sarcopenia and Muscle. 2022 Feb 2;13(2):781–94.\
  39. Tan LF, Sia CH, Merchant RA. Sarcopenia and sarcopenic obesity in cardiovascular disease: a comprehensive review. Singapore Medical Journal. 2025 Aug 1;
  40. Torres‐Leal FL, Fonseca‐Alaniz MH, Rogero MM, Tirapegui J. The role of inflamed adipose tissue in the insulin resistance. Cell Biochemistry and Function. 2010 Nov 23;28(8):623–31.
  41. Kwon H, Pessin JE. Adipokines Mediate Inflammation and Insulin Resistance. Frontiers in Endocrinology. 2013;4.
  42. Sarcopenic Obesity: Causes, Diagnosis & Treatment [Internet]. Obesity Medicine Association. 2024. Available from: https://obesitymedicine.org/blog/sarcopenic-obesity/
  43. Khamassi S, Fatma Boukhayatia, Haifa Abdesselem, Emna Bornaz, Kamilia Ounaissa, Houda Bouhajja, et al. Sarcopenic Obesity in Adult Patients: Prevalence and Risk Factors. Nutrition and Metabolic Insights. 2025 Jun 1;18.
  44. Kang YE, Kim JM, Joung KH, Lee JH, You BR, Choi MJ, et al. The Roles of Adipokines, Proinflammatory Cytokines, and Adipose Tissue Macrophages in Obesity-Associated Insulin Resistance in Modest Obesity and Early Metabolic Dysfunction. López Lluch G, editor. PLOS ONE [Internet]. 2016 Apr 21 [cited 2019 Nov 26];11(4):e0154003. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154003
  45. Al-Mansoori L, Al-Jaber H, Prince MS, Elrayess MA. Role of Inflammatory Cytokines, Growth Factors and Adipokines in Adipogenesis and Insulin Resistance. Inflammation. 2021 Sep 18;45(1).
  46. Mittendorfer B, Johnson JD, Solinas G, Jansson PA. Insulin Hypersecretion as Promoter of Body Fat Gain and Hyperglycemia. Diabetes [Internet]. 2024 May 20;73(6):837–43. Available from: https://diabetesjournals.org/diabetes/article/73/6/837/154590/Insulin-Hypersecretion-as-Promoter-of-Body-Fat
  47. Altuntaş Y. Postprandial Reactive Hypoglycemia. Şişli Etfal Hastanesi tıp Bülteni [Internet]. 2019 Aug 28;53(3):215–20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192270/
  48. Brun JF, Fedou C, Mercier J. Postprandial reactive hypoglycemia. Diabetes & Metabolism [Internet]. 2000 Nov 1;26(5):337–51. Available from: https://pubmed.ncbi.nlm.nih.gov/11119013/
  49. Stuart K, Field A, Raju J, Ramachandran S. Postprandial Reactive Hypoglycaemia: Varying Presentation Patterns on Extended Glucose Tolerance Tests and Possible Therapeutic Approaches. Case Reports in Medicine [Internet]. 2013 [cited 2020 Feb 3];2013:1–5. Available from: https://www.hindawi.com/journals/crim/2013/273957/
  50. Reactive Hypoglycemia: What Is It? [Internet]. WebMD. Available from: https://www.webmd.com/a-to-z-guides/reactive-hypoglycemia
  51. Reactive hypoglycemia: Causes, symptoms, and treatment [Internet]. www.medicalnewstoday.com. 2021. Available from: https://www.medicalnewstoday.com/articles/reactive-hypoglycemia
  52. Flanagan EW, Most J, Mey JT, Redman LM. Calorie Restriction and Aging in Humans. Annual Review of Nutrition. 2020 Sep 23;40(1):105–33.
  53. Most J, Redman LM. Impact of calorie restriction on energy metabolism in humans. Experimental Gerontology [Internet]. 2020 May;133:110875. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9036397/
  54. Lv S, Shen Q, Li H, Chen Q, Xie W, Li Y, et al. Caloric restriction delays age-related muscle atrophy by inhibiting 11β−HSD1 to promote the differentiation of muscle stem cells. Frontiers in Medicine. 2023 Jan 5;9.
  55. Ham DJ, Börsch A, Chojnowska K, Lin S, Leuchtmann AB, Ham AS, et al. Distinct and additive effects of calorie restriction and rapamycin in aging skeletal muscle. Nature Communications [Internet]. 2022 Apr 19;13(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018781/
  56. Biolo G, Ciocchi B, Stulle M, Bosutti A, Barazzoni R, Zanetti M, et al. Calorie restriction accelerates the catabolism of lean body mass during 2 wk of bed rest. The American Journal of Clinical Nutrition [Internet]. 2007 Aug 1;86(2):366–72. Available from: https://academic.oup.com/ajcn/article/86/2/366/4632953
  57. Campbell WW, Haub MD, Wolfe RR, Ferrando AA, Sullivan DH, Apolzan JW, et al. Resistance Training Preserves Fat-free Mass Without Impacting Changes in Protein Metabolism After Weight Loss in Older Women. Obesity. 2009 Feb 26;
  58. Hurtado MD, Saadedine M, Kapoor E, Shufelt CL, Faubion SS. Weight Gain in Midlife Women. Current obesity reports. 2024 Feb 28;
  59. How Cortisol Breaks Down Muscle & Prevents Protein Synthesis [Internet]. BodyHealth.com LLC. 2024. Available from: https://bodyhealth.com/blogs/news/cortisol-breaks-down-muscle-prevents-protein-synthesis
  60. Youmshajekian L. Cortisol Rises during Intense workouts. Is That really a Bad thing? [Internet]. Health. 2025. Available from: https://www.nationalgeographic.com/health/article/exercise-effect-cortisol-level
  61. Torres R, Koutakis P, Forsse J. The Effects of Different Exercise Intensities and Modalities on Cortisol Production in Healthy Individuals: A Review. Journal of Exercise and Nutrition. 2021 Oct 28;4(4).
  62. Ishaq I, Noreen S, Aja PM, Ayomide Victor Atoki. Role of protein intake in maintaining muscle mass composition among elderly females suffering from sarcopenia. Frontiers in Nutrition. 2025 May 12;12.
  63. Staff L. How Much Cardio is Too Much? Don’t Sabotage Your Client’s Fitness Goals [Internet]. blog.lionel.edu. Available from: https://blog.lionel.edu/how-much-cardio-is-too-much
  64. Wang J, Fan S, Wang J. Resistance training enhances metabolic and muscular health and reduces systemic inflammation in middle-aged and older adults with type 2 diabetes: a meta-analysis. Diabetes Research and Clinical Practice [Internet]. 2025 Oct 15;229:112941. Available from: https://www.sciencedirect.com/science/article/pii/S0168822725009556
  65. Ihalainen JK, Inglis A, Mäkinen T, Newton RU, Kainulainen H, Kyröläinen H, et al. Strength Training Improves Metabolic Health Markers in Older Individual Regardless of Training Frequency. Frontiers in Physiology [Internet]. 2019 Feb 1;10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367240/
  66. Tomé D. Muscle Protein Synthesis and Muscle Mass in Healthy Older Men. The Journal of Nutrition. 2017 Nov 1;147(12):2209–11.
  67. Hiol AN, Pamela, Conlon CA, Mumme KD, Beck KL. Protein intake, distribution, and sources in community-dwelling older adults living in Auckland, New Zealand. Nutrition and healthy aging. 2023 Oct 13;8(1):171–81.
  68. Wijnhoven HAH, Niskanen RT, Reinders I, Suominen MH, Jyväkorpi SK, Brouwer IA, et al. The role of protein intake distribution across meals in maintenance of physical performance and muscle strength in older adults: An exploratory study based on secondary data analysis of the PRevention Of Malnutrition In Senior Subjects in the EU (PROMISS) trial. Clinical Nutrition Open Science. 2025 Aug;62:89–101.
  69. Layman DK. Impacts of protein quantity and distribution on body composition. Frontiers in nutrition. 2024 May 3;11.
  70. Hiol AN, Hurst PR von, Conlon CA, Beck KL. Associations of protein intake, sources and distribution on muscle strength in community-dwelling older adults living in Auckland, New Zealand. Journal of Nutritional Science [Internet]. 2023 Jan 1 [cited 2023 Nov 29];12:e94. Available from: https://www.cambridge.org/core/journals/journal-of-nutritional-science/article/associations-of-protein-intake-sources-and-distribution-on-muscle-strength-in-communitydwelling-older-adults-living-in-auckland-new-zealand/98EA0EE387F88D64FFE4CA28EE957304
  71. Bellini A, Nicolò A, Bazzucchi I, Sacchetti M. The Effects of Postprandial Walking on the Glucose Response after Meals with Different Characteristics. Nutrients. 2022 Mar 4;14(5):1080.
  72. The Connection Between Menopause & Belly Fat [Internet]. www.uhhospitals.org. Available from: https://www.uhhospitals.org/blog/articles/2023/08/the-connection-between-menopause-and-belly-fat
  73. Weight Gain During Menopause: Understanding Metabolic Changes [Internet]. Function Smart Physical Therapy in San Diego, CA. 2025 [cited 2026 Jan 26]. Available from: https://functionsmart.com/weight-gain-during-menopause-understanding-metabolic-changes/
  74. Hashimoto K, Dora K, Murakami Y, Matsumura T, I Wayan Yuuki, Yang S, et al. Positive impact of a 10-min walk immediately after glucose intake on postprandial glucose levels. Scientific Reports [Internet]. 2025 Jul 2;15(1). Available from: https://www.nature.com/articles/s41598-025-07312-y
  75. Iida Y, Takeishi S, Fushimi N, Tanaka K, Mori A, Sato Y. Effect of postprandial moderate-intensity walking for 15-min on glucose homeostasis in type 2 diabetes mellitus patients. Diabetology International. 2020 Apr 3;11(4):383–7.
  76. Ji C, Jiang T, Liu L, Zhang J, You L. Continuous glucose monitoring combined with artificial intelligence: redefining the pathway for prediabetes management. Frontiers in Endocrinology. 2025 May 26;16.
  77. Lee YB, Kim G, Ji Eun Jun, Park H, Woo Je Lee, Hwang YC, et al. An integrated digital health care platform for diabetes management with ai-based dietary management: 48-Week results from a randomized controlled trial. Diabetes Care [Internet]. 2023 Feb 23;46(5). Available from: https://diabetesjournals.org/care/article/46/5/959/148541/An-Integrated-Digital-Health-Care-Platform-for
  78. Veluvali A, Dehghani Zahedani A, Hosseinian A, Aghaeepour N, McLaughlin T, Woodward M, et al. Impact of digital health interventions on glycemic control and weight management. npj Digital Medicine [Internet]. 2025 Jan 9;8(1). Available from: https://www.nature.com/articles/s41746-025-01430-7
  79. González-Rivas JP, Seyedi SA, Mechanick JI. Artificial Intelligence Enabled Lifestyle Medicine in Diabetes Care: A Narrative Review. American journal of lifestyle medicine [Internet]. 2025;15598276251359185. Available from: https://pubmed.ncbi.nlm.nih.gov/40687630/
  80. Bushra Urooj, Ko Y, Seongwon Na, Kim IO, Lee EH, Cho S, et al. Implementation of fully automated AI-integrated system for body composition assessment on CT for opportunistic sarcopenia screening: Multicenter prospective study (Preprint). JMIR Formative Research. 2025 Jun 2;9:e69940–0.
  81. Dilmurod Turimov Mustapoevich, Kim W. Machine Learning Applications in Sarcopenia Detection and Management: A Comprehensive Survey. Healthcare. 2023 Sep 7;11(18):2483–3.
  82. Gu S, Wang L, Han R, Liu X, Wang Y, Chen T, et al. Detection of sarcopenia using deep learning-based artificial intelligence body part measure system (AIBMS). Frontiers in Physiology [Internet]. 2023 Jan 26;14:1092352. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909827/
  83. Nowak S, Theis M, Wichtmann BD, Faron A, Froelich MF, Tollens F, et al. End-to-end automated body composition analyses with integrated quality control for opportunistic assessment of sarcopenia in CT. European Radiology. 2021 Sep 30;32(5):3142–51.
  84. Ghaderi M, Chitzan-Zadeh K, Mokarami M, Mokarami M, Shokoohi M, Vafa RG. Revolutionizing diabetes management: Artificial intelligence (AI) from assessment to advanced monitoring. Next Research. 2025 Sep;2(3):100472.
  85. Chen B, Wang Y, Xie X, Fan B, Zhang W, Sun G. Trends in AI-based diagnosis and intervention of metabolic diseases: a bibliometric analysis of the literature from 2000 to 2024. Frontiers in Medicine [Internet]. 2025 Dec 5;12. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12714997/
  86. Yousefi F, Naye F, Ouellet S, Yameogo A, Sasseville M, Bergeron F, et al. Artificial Intelligence (AI) in Health Promotion and Disease Reduction: A Rapid Review (Preprint). Journal of Medical Internet Research [Internet]. 2025 Jan 7; Available from: https://www.jmir.org/2025/1/e70381
  87. Digital programme improves metabolic health in diabetes [Internet]. pharmaphorum. 2023 [cited 2026 Jan 26]. Available from: https://pharmaphorum.com/news/digital-programme-improves-metabolic-health-diabetes

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading